Yes, Continue Both Warfarin and Therapeutic Enoxaparin Together as a Bridge
When a patient on chronic warfarin is hospitalized and therapeutic enoxaparin (Lovenox) is ordered, you should administer both medications concurrently until the INR reaches therapeutic range (≥2.0 for at least 24 hours), then discontinue the enoxaparin. This is standard bridging therapy for acute venous thromboembolism (VTE) treatment or high-risk thrombotic conditions.
How to Manage the Bridge
Initial Phase (Days 1-5+)
- Start therapeutic enoxaparin immediately at 1 mg/kg subcutaneously every 12 hours (or 1.5 mg/kg once daily) 1, 2
- Continue the patient's home warfarin dose or initiate warfarin at 2.5-5 mg daily, adjusting based on INR 1
- Overlap both medications for a minimum of 5 days 3, 4, 2
Transition Point
- Check INR daily starting on day 3-4 of overlap therapy
- Discontinue enoxaparin only when:
Critical Timing Details
The FDA label for Lovenox explicitly states: "warfarin sodium therapy should be initiated when appropriate (usually within 72 hours of Lovenox). Lovenox should be continued for a minimum of 5 days and until a therapeutic oral anticoagulant effect has been achieved (International Normalization Ratio 2.0 to 3.0)" 2. This means you must give both drugs together - this is not optional.
Common Clinical Scenarios
Acute VTE Treatment (DVT/PE)
This is the most common inpatient scenario requiring bridging. The enoxaparin provides immediate anticoagulation while warfarin takes 5+ days to reach therapeutic effect 1, 3, 2. Average duration is 7 days of overlap, though up to 17 days has been studied 2.
High Thrombotic Risk Conditions
For patients with mechanical heart valves (especially mitral position), recent VTE (<3 months), or antiphospholipid syndrome, therapeutic bridging is appropriate 5, 6, 7, 4.
Critical Pitfalls to Avoid
Do NOT stop enoxaparin prematurely - The most dangerous error is discontinuing enoxaparin before adequate warfarin effect. Warfarin initially creates a hypercoagulable state by depleting protein C before depleting clotting factors, requiring the enoxaparin "bridge" for protection 6.
Do NOT give subtherapeutic enoxaparin doses - If therapeutic anticoagulation is indicated, prophylactic doses (40 mg daily) are inadequate. Use 1 mg/kg every 12 hours or 1.5 mg/kg once daily 1, 3, 2.
Do NOT bridge if this is perioperative warfarin interruption - The scenario you describe (patient on home warfarin, now inpatient with therapeutic enoxaparin ordered) suggests acute treatment, not perioperative bridging. For elective procedures, recent evidence shows bridging increases bleeding without reducing thrombosis in most patients 8, 9, 10. However, your scenario appears to be therapeutic treatment, not perioperative management.
When NOT to Bridge
Recent high-quality evidence from the BRIDGE trial and subsequent guidelines 8, 9 demonstrate that perioperative bridging is NOT recommended for most patients undergoing elective procedures, even those at moderate thrombotic risk (atrial fibrillation, remote VTE >3 months ago). Bridging increases major bleeding 2-3 fold without reducing stroke risk 9, 10.
However, this does not apply to your scenario - a hospitalized patient receiving therapeutic enoxaparin alongside warfarin is receiving acute VTE treatment or management of acute thrombotic risk, not perioperative bridging.
Monitoring Requirements
- Daily INR once warfarin started until stable in therapeutic range
- No routine anti-Xa monitoring needed for standard-dose enoxaparin in patients with normal renal function 2
- Adjust enoxaparin dose if creatinine clearance <30 mL/min: reduce to 1 mg/kg once daily 2
- Watch for bleeding signs - major bleeding risk is 3-4% with therapeutic enoxaparin 11
Cost and Duration Considerations
The average overlap duration is 7 days, with the therapeutic INR typically achieved by days 5-7 2. Continuing both medications longer than necessary increases costs significantly (approximately $967 incremental cost per bridging episode) without clear benefit 12.